- Home
- BCAX vs ANAB Comparison
BCAX vs ANAB Comparison
Compare BCAX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- ANAB
- Stock Information
- Founded
- BCAX 2018
- ANAB 2005
- Country
- BCAX United States
- ANAB United States
- Employees
- BCAX N/A
- ANAB N/A
- Industry
- BCAX
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- BCAX
- ANAB Health Care
- Exchange
- BCAX NYSE
- ANAB Nasdaq
- Market Cap
- BCAX 541.0M
- ANAB 621.1M
- IPO Year
- BCAX 2024
- ANAB 2017
- Fundamental
- Price
- BCAX $10.53
- ANAB $24.69
- Analyst Decision
- BCAX Strong Buy
- ANAB Buy
- Analyst Count
- BCAX 7
- ANAB 10
- Target Price
- BCAX $29.17
- ANAB $49.00
- AVG Volume (30 Days)
- BCAX 329.8K
- ANAB 522.6K
- Earning Date
- BCAX 08-16-2025
- ANAB 08-12-2025
- Dividend Yield
- BCAX N/A
- ANAB N/A
- EPS Growth
- BCAX N/A
- ANAB N/A
- EPS
- BCAX N/A
- ANAB N/A
- Revenue
- BCAX N/A
- ANAB $111,872,000.00
- Revenue This Year
- BCAX N/A
- ANAB N/A
- Revenue Next Year
- BCAX N/A
- ANAB $24.39
- P/E Ratio
- BCAX N/A
- ANAB N/A
- Revenue Growth
- BCAX N/A
- ANAB 387.20
- 52 Week Low
- BCAX $7.80
- ANAB $12.21
- 52 Week High
- BCAX $28.09
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- ANAB 45.70
- Support Level
- BCAX N/A
- ANAB $23.61
- Resistance Level
- BCAX N/A
- ANAB $28.50
- Average True Range (ATR)
- BCAX 0.00
- ANAB 1.24
- MACD
- BCAX 0.00
- ANAB -0.35
- Stochastic Oscillator
- BCAX 0.00
- ANAB 22.17
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).